| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.94B | +16.7% |
| Cost of Revenue | $957.8M | -7.5% |
| R&D Expense | $147.2M | -10.1% |
| SG&A Expense | $1.18B | +20.1% |
| Operating Income | $479.8M | +189.1% |
| Pre-tax Income | $605.1M | +401.2% |
| Income Tax | $67.2M | +278.8% |
| Net Income | $537.9M | +422.3% |
| EPS (Basic) | $3.98 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $526.2M | -32.9% |
| Short-term Investments | $31.1M | -70.6% |
| Accounts Receivable | $678.9M | +21.7% |
| Inventory | $759.3M | +15.2% |
| Current Assets | $2.13B | -2.4% |
| Total Assets | $5.30B | +1.0% |
| Current Liabilities | $498.5M | -41.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $753.4M | +44.7% |
| Capital Expenditures | $164.7M | +42.7% |
| Investing Cash Flow | -$355.0M | -101.7% |
| Financing Cash Flow | -$679.2M | -2352.2% |
| Free Cash Flow | $588.8M | +45.3% |
| +423.7% |
| EPS (Diluted) | $3.92 | +422.7% |
| Total Liabilities |
| $729.5M |
| -32.1% |
| Stockholders' Equity | $4.57B | +9.5% |